Incidence, Risk Factors, Severity and Prognosis of Necrotizing Enterocolitis in Turkey

April 10, 2020 updated by: Tolga Hasan Çelik, MD, Turkish Neonatal Society

Incidence, Risk Factors, Severity and Prognosis of Necrotizing Enterocolitis in Turkey: A Prospective Multicentre Study

Necrotizing enterocolitis (NEC) is a gastrointestinal system disease characterized by inflammatory necrosis of the intestine mainly seen in premature infants, and continues to be an important cause of mortality and morbidity in neonatal intensive care units all over the world. Although it is more common in premature infants, it is also seen in term babies when the intestine is ischemic. Although the major problem in premature babies is the immaturity of the intestine, many factors contributing to immaturity play a role in the pathogenesis of NEC.

Study Overview

Detailed Description

Necrotizing enterocolitis (NEC) is a gastrointestinal system disease characterized by inflammatory necrosis of the intestine mainly seen in premature infants, and continues to be an important cause of mortality and morbidity in neonatal intensive care units all over the world. Although it is more common in premature infants, it is also seen in term babies when the intestine is ischemic. Although the major problem in premature babies is the immaturity of the intestine, many factors contributing to immaturity play a role in the pathogenesis of NEC.

With this study project, which is planned as a national multicenter prospective study, the incidence of necrotizing enterocolitis in newborn infants born in neonatal intensive care units in our country and the risk factors associated with the NEC, especially the detailed feeding history of the patient (when the first feeding is nourished, antibiotics and other treatments that are being used). Most epidemiological data such as the most common stage of the disease, treatment, prognosis, comparison with the data of other countries will provide important information for the neonatal health of our country.

The aim of this study was to determine the factors affecting the emergence of NEC in neonatal intensive care units and to determine the frequency of NEC.

Study Hypothesis: Delayed enteral feeding, intensive use of antibiotics and nutrients other than breast milk increase the incidence of necrotizing enterocolitis.

Study Type

Observational

Enrollment (Actual)

500

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Ankara, Turkey, 06100
        • Tolga Hasan Çelik, MD
      • Ankara, Turkey, 06100
        • Tolga Hasan Çelik

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 day to 3 months (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Newborns diagnosed with NEC in neonatal intensive care units.

Description

Inclusion Criteria:

  • Newborns diagnosed with NEC in neonatal intensive care units

Exclusion Criteria:

  • Major congenital anomaly,
  • congenital heart disease (except for atrial septal defect, ventricular septal defect, patent ductus arteriosus)
  • Chromosomal anomaly
  • Inherited metabolic disease
  • Hypoxic ischemic encephalopathy
  • Newborns who died within the first 48 hours of life

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of Necrotizing Enterocolitis
Time Frame: 1 year
Incidence: frequency of NEC during study period
1 year
Risk factors for mild and severe necrotizing enterocolitis
Time Frame: 1 year
erytrocyte/FFP/trombocyte transfusions,PDA closing therapy, umbilical artery catheterisation,
1 year
Initiation of enteral feeding time, choice of breastfeeding or formula
Time Frame: 1 year
nutrition: breastfeeding of formula, delayed enteral feeding
1 year
Meconium discharge time
Time Frame: 1 year
meconium discharge time (hour)
1 year
probiotic usage
Time Frame: 1 year
probiotic usage, type of probiotic preparation
1 year
severity of necrotizing enrerocolitis
Time Frame: 1 year
Grade of NEC disease according to modified Bell Criteria
1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prognosis
Time Frame: 1 year
complications: intestinal perforation, requirement of surgery, short bowell syndrome), mortality rate.
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Tolga H Çelik, MD, Hacettepe University Faculty of Medicine Department of Pediatrics

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2019

Primary Completion (Actual)

March 1, 2020

Study Completion (Actual)

April 1, 2020

Study Registration Dates

First Submitted

March 5, 2019

First Submitted That Met QC Criteria

April 10, 2020

First Posted (Actual)

April 14, 2020

Study Record Updates

Last Update Posted (Actual)

April 14, 2020

Last Update Submitted That Met QC Criteria

April 10, 2020

Last Verified

April 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

IPD Plan Description

This study project is planned as a national multi-center study. This study will be carried out through a Web Based Multicenter Work System, which was formed by the Turkish Neonatal Society.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Necrotizing Enterocolitis

3
Subscribe